Ironwood Pharmaceuticals, Inc. (IRWD)
USD 0.93
(2.24%)
USD 0.93
(2.24%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -1 Billion USD | -672.5% |
| 2022 | 175.06 Million USD | -66.87% |
| 2021 | 528.44 Million USD | 397.71% |
| 2020 | 106.17 Million USD | 793.33% |
| 2019 | -15.31 Million USD | 94.58% |
| 2018 | -282.36 Million USD | -141.47% |
| 2017 | -116.93 Million USD | -43.12% |
| 2016 | -81.7 Million USD | 42.73% |
| 2015 | -142.66 Million USD | 24.76% |
| 2014 | -189.61 Million USD | 30.49% |
| 2013 | -272.81 Million USD | -275.65% |
| 2012 | -72.62 Million USD | -11.98% |
| 2011 | -64.85 Million USD | -22.41% |
| 2010 | -52.98 Million USD | 25.57% |
| 2009 | -71.18 Million USD | -32.13% |
| 2008 | -53.87 Million USD | -2.13% |
| 2007 | -52.75 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -4.16 Million USD | -282.89% |
| 2024 Q2 | -860 Thousand USD | 79.34% |
| 2023 Q3 | 15.32 Million USD | 101.44% |
| 2023 Q4 | -1.08 Million USD | -107.09% |
| 2023 Q1 | 45.71 Million USD | -6.45% |
| 2023 Q2 | -1.06 Billion USD | -2423.55% |
| 2023 FY | -1 Billion USD | -672.5% |
| 2022 Q2 | 37.08 Million USD | -4.44% |
| 2022 Q3 | 50.31 Million USD | 35.7% |
| 2022 Q4 | 48.86 Million USD | -2.88% |
| 2022 FY | 175.06 Million USD | -66.87% |
| 2022 Q1 | 38.8 Million USD | -6.22% |
| 2021 Q4 | 41.37 Million USD | -25.91% |
| 2021 FY | 528.44 Million USD | 397.71% |
| 2021 Q2 | 391.3 Million USD | 880.07% |
| 2021 Q1 | 39.92 Million USD | -7.59% |
| 2021 Q3 | 55.84 Million USD | -85.73% |
| 2020 FY | 106.17 Million USD | 793.33% |
| 2020 Q3 | 34.42 Million USD | 36.58% |
| 2020 Q2 | 25.2 Million USD | 653.48% |
| 2020 Q1 | 3.34 Million USD | -93.01% |
| 2020 Q4 | 43.2 Million USD | 25.51% |
| 2019 Q1 | -59.28 Million USD | -282.65% |
| 2019 Q3 | 20.64 Million USD | 68.1% |
| 2019 Q4 | 47.85 Million USD | 131.78% |
| 2019 FY | -15.31 Million USD | 94.58% |
| 2019 Q2 | 12.28 Million USD | 120.72% |
| 2018 Q3 | -174.35 Million USD | -253.08% |
| 2018 FY | -282.36 Million USD | -141.47% |
| 2018 Q1 | -43.14 Million USD | -457.0% |
| 2018 Q2 | -49.38 Million USD | -14.45% |
| 2018 Q4 | -15.49 Million USD | 91.11% |
| 2017 Q4 | 12.08 Million USD | 137.42% |
| 2017 Q3 | -32.29 Million USD | 26.97% |
| 2017 FY | -116.93 Million USD | -43.12% |
| 2017 Q2 | -44.22 Million USD | 15.77% |
| 2017 Q1 | -52.5 Million USD | -288.75% |
| 2016 FY | -81.7 Million USD | 42.73% |
| 2016 Q4 | -13.5 Million USD | 59.33% |
| 2016 Q3 | -33.2 Million USD | -53.0% |
| 2016 Q2 | -21.7 Million USD | -63.21% |
| 2016 Q1 | -13.29 Million USD | 5.27% |
| 2015 Q4 | -14.03 Million USD | 70.38% |
| 2015 Q2 | -48.02 Million USD | -44.54% |
| 2015 Q3 | -47.39 Million USD | 1.31% |
| 2015 Q1 | -33.22 Million USD | 11.75% |
| 2015 FY | -142.66 Million USD | 24.76% |
| 2014 Q1 | -49.62 Million USD | 4.54% |
| 2014 Q3 | -41.98 Million USD | 30.43% |
| 2014 Q4 | -37.64 Million USD | 10.34% |
| 2014 FY | -189.61 Million USD | 30.49% |
| 2014 Q2 | -60.35 Million USD | -21.62% |
| 2013 FY | -272.81 Million USD | -275.65% |
| 2013 Q2 | -65.14 Million USD | 30.62% |
| 2013 Q3 | -61.77 Million USD | 5.18% |
| 2013 Q4 | -51.98 Million USD | 15.85% |
| 2013 Q1 | -93.9 Million USD | -114.12% |
| 2012 Q1 | -35.6 Million USD | -410.48% |
| 2012 FY | -72.62 Million USD | -11.98% |
| 2012 Q3 | 47.63 Million USD | 216.74% |
| 2012 Q2 | -40.8 Million USD | -14.61% |
| 2012 Q4 | -43.85 Million USD | -192.06% |
| 2011 Q2 | -18.84 Million USD | -2.41% |
| 2011 Q4 | -6.97 Million USD | 66.2% |
| 2011 FY | -64.85 Million USD | -22.41% |
| 2011 Q3 | -20.63 Million USD | -9.49% |
| 2011 Q1 | -18.4 Million USD | -57.93% |
| 2010 Q4 | -11.65 Million USD | -40.88% |
| 2010 FY | -52.98 Million USD | 25.57% |
| 2010 Q2 | -17.13 Million USD | -7.61% |
| 2010 Q1 | -15.92 Million USD | 33.46% |
| 2010 Q3 | -8.27 Million USD | 51.74% |
| 2009 FY | -71.18 Million USD | -32.13% |
| 2009 Q1 | -17.96 Million USD | -60.04% |
| 2009 Q2 | -18.38 Million USD | -2.32% |
| 2009 Q3 | -10.9 Million USD | 40.7% |
| 2009 Q4 | -23.93 Million USD | -119.5% |
| 2008 Q4 | -11.22 Million USD | 0.0% |
| 2008 FY | -53.87 Million USD | -2.13% |
| 2007 FY | -52.75 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Esperion Therapeutics, Inc. | -209.24 Million USD | -378.972% |
| Theratechnologies Inc. | -23.95 Million USD | -4083.491% |
| Safety Shot Inc | -15.08 Million USD | -6544.807% |
| Cosmos Health Inc. | -18.54 Million USD | -5305.046% |
| Cronos Group Inc. | -73.96 Million USD | -1255.055% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | -2275.03% |
| Organogenesis Holdings Inc. | 4.94 Million USD | 20367.725% |
| Universe Pharmaceuticals INC | -6.16 Million USD | -16162.033% |
| ProPhase Labs, Inc. | -16.78 Million USD | -5872.107% |
| Sonoma Pharmaceuticals, Inc. | -4.83 Million USD | -20628.831% |
| Dynavax Technologies Corporation | -6.38 Million USD | -15586.946% |
| Radius Health, Inc. | -25.79 Million USD | -3786.003% |
| China SXT Pharmaceuticals, Inc. | -3.09 Million USD | -32245.608% |
| Alvotech | -551.73 Million USD | -81.654% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | -22142.104% |
| Alpha Teknova, Inc. | -36.78 Million USD | -2624.956% |
| Intra-Cellular Therapies, Inc. | -139.67 Million USD | -617.556% |
| SCYNEXIS, Inc. | 67.04 Million USD | 1594.964% |
| Harrow Health, Inc. | -24.41 Million USD | -4005.686% |
| Biofrontera Inc. | -20.13 Million USD | -4878.585% |
| DURECT Corporation | -27.62 Million USD | -3528.146% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | 76257.979% |
| ANI Pharmaceuticals, Inc. | 18.77 Million USD | 5437.02% |
| OptiNose, Inc. | -35.48 Million USD | -2724.561% |
| RedHill Biopharma Ltd. | 23.91 Million USD | 4290.663% |
| Aquestive Therapeutics, Inc. | -7.87 Million USD | -12634.93% |
| Cumberland Pharmaceuticals Inc. | -6.27 Million USD | -15860.948% |
| SIGA Technologies, Inc. | 68.06 Million USD | 1572.391% |
| Lifecore Biomedical, Inc. | 12.01 Million USD | 8442.953% |
| Shineco, Inc. | -22.44 Million USD | -4364.512% |
| Phibro Animal Health Corporation | 2.41 Million USD | 41583.402% |
| Procaps Group S.A. | 42.54 Million USD | 2455.992% |
| TherapeuticsMD, Inc. | -10.27 Million USD | -9651.304% |
| Regencell Bioscience Holdings Limited | -4.3 Million USD | -23197.931% |
| Viatris Inc. | 54.7 Million USD | 1932.247% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | -22142.104% |
| Rockwell Medical, Inc. | -8.43 Million USD | -11776.277% |
| Incannex Healthcare Limited | -18.45 Million USD | -5329.541% |
| Aytu BioPharma, Inc. | -15.84 Million USD | -6225.669% |
| Tilray Brands, Inc. | -244.98 Million USD | -309.109% |
| Collegium Pharmaceutical, Inc. | 48.15 Million USD | 2181.277% |
| PetIQ, Inc. | 2.13 Million USD | 47131.394% |
| Silver Spike Investment Corp. | 7.34 Million USD | 13754.281% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 501.377% |
| Journey Medical Corporation | -3.85 Million USD | -25911.913% |
| Alimera Sciences, Inc. | -20.13 Million USD | -4878.338% |
| Petros Pharmaceuticals, Inc. | -8.16 Million USD | -12177.544% |
| Assertio Holdings, Inc. | -331.94 Million USD | -201.932% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6.59 Million USD | -15102.201% |
| Embecta Corp. | 70.4 Million USD | 1523.635% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | -4896.878% |
| Procaps Group, S.A. | 42.54 Million USD | 2455.992% |
| PainReform Ltd. | -9.34 Million USD | -10626.017% |
| Avadel Pharmaceuticals plc | -160.27 Million USD | -525.321% |
| Hempacco Co., Inc. | -13.12 Million USD | -7535.478% |
| Talphera, Inc. | -18.39 Million USD | -5347.839% |
| Pacira BioSciences, Inc. | 41.95 Million USD | 2488.843% |
| Alvotech | -551.73 Million USD | -81.654% |
| Lantheus Holdings, Inc. | 326.66 Million USD | 406.813% |
| Kamada Ltd. | 8.28 Million USD | 12198.491% |
| Indivior PLC | 2 Million USD | 50211.95% |
| Currenc Group, Inc. | -15.3 Million USD | -6447.779% |
| Evoke Pharma, Inc. | -7.79 Million USD | -12761.923% |
| Flora Growth Corp. | -57.03 Million USD | -1657.204% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | -4896.878% |
| Evolus, Inc. | -61.68 Million USD | -1524.769% |
| HUTCHMED (China) Limited | 100.78 Million USD | 1094.482% |
| Amphastar Pharmaceuticals, Inc. | 137.54 Million USD | 828.663% |
| Akanda Corp. | -32.27 Million USD | -3005.304% |